Clostridium difficile treatment in neutropenic patients: Clinical outcomes of metronidazole,vancomycin,combinations,and switch therapy

Abstract

Background

Clostridium difficile infection treatment guidelines exist for immunocompetent patients; however, there is a paucity of data evaluating clinical outcomes and time to C. difficile-associated diarrhea resolution in neutropenic patients.

Objective

To assess clinical outcomes in neutropenic patients treated with metronidazole, oral vancomycin, the combination of metronidazole plus oral vancomycin, and switch of metronidazole to oral vancomycin.

Methods

This retrospective, observational cohort study assessed adult neutropenic inpatients with C. difficile-associated diarrhea treated with metronidazole, oral vancomycin, combination (metronidazole and oral vancomycin), or switch therapy (metronidazole to oral vancomycin). The primary outcome was time to diarrhea resolution based on treatment regimen. Secondary outcomes included C. difficile-associated diarrhea resolution of diarrhea by day 14, recurrence, and occurrence of major complications.

Results

Overall, 44 patients met full inclusion criteria (52.2% metronidazole monotherapy, 22.7% combination, and 25.0% switch therapy). Two patients on oral vancomycin monotherapy were excluded due to insufficient sample size. Overall time to C. difficile-associated diarrhea resolution was 9.1 ± 10.7 days. The Cox regression results suggested both switch and combination therapy were associated with 65.5% (p = 0.002) and 65.9% (p = 0.046) longer time to C. difficile-associated diarrhea resolution compared to metronidazole monotherapy, respectively. An increasing absolute neutrophil count was associated with an increase in C. difficile-associated diarrhea resolution (p = 0.007).

Conclusion

Switch or combination therapy was associated with a prolonged time to C. difficile-associated diarrhea resolution. The decision to use switch or combination therapy may represent a surrogate marker for more severe disease and need for therapy escalation. It is unknown if initial therapy with oral vancomycin would provide better outcomes as this could not be assessed.

Keywords

metronidazole neutropenia vancomycin

Get full access to this article

View all access options for this article.

References

Surawicz

Brandt

Binion

et al.

Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478–498. quiz 499.

Dubberke

Olsen

. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012; 55: S88–S92.

Leffler

Lamont

. Clostridium difficile infection. N Engl J Med 2015; 372: 1539–1548.

Cohen

Gerding

Johnson

et al.

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431–455.

Gorschluter

Glasmacher

Hahn

et al.

Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2001; 33: 786–791.

Baden

Bensinger

Angarone

et al.

Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2012; 10: 1412–1445.

Bishop

Castillo

. Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. Leuk Lymphoma 2012; 53: 1617–1619.

Parmar

Bhatt

Yang

et al.

A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. J Oncol Pharm Pract 2014; 20: 172–182.

Charlson

Pompei

Ales

et al.

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.

10.

Klastersky

Paesmans

Rubenstein

et al.

The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038–3051.

11.

Belmares

Gerding

Parada

et al.

Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect 2007; 55: 495–501.

12.

Zar

Bakkanagari

Moorthi

et al.

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302–307.

13.

Boxer

. How to approach neutropenia. Hematology Am Soc Hematol Educ Program 2012; 2012: 174–182.

14.

United States Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), NIH Publication No. 09-5410, https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (2010, accessed 24 October 2017).

15.

Cornely

Miller

Fantin

et al.

Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 2013; 31: 2493–2499.

16.

Skrepnek

Olvey

Sahai

. Econometric approaches in evaluating costs and outcomes within pharmacoeconomic analyses. Pharm Policy Law 2012; 14: 105–122.

17.

Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. In: LM Le Cam, J Neyman (eds.) Proceedings of the fifth Berkeley symposium on mathematical statistics and probability, vol. 1, 1967, pp.221–233, Berkeley, CA: University of California Press.

18.

White

. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica 1980; 48: 817–838.

19.

Alonso

Treadway

Hanna

et al.

Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2012; 54: 1053–1063.

20.

Wenisch

Schmid

Kuo

et al.

Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection. Antimicrob Agents Chemother 2012; 56: 1974–1978.